University of L'Aquila   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: L'Aquila Italy (1596)

Organization Overview

First Clinical Trial
1994
NCT01442519
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Dr. Leonardo Mancini | Prof. Roberto Giacomelli | San Salvatore Academic Hospital of L'Aquila | San Salvatore Hospital of L'Aquila | Tommaso Pizzolante | University of L'Aquila

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Genetic Diseases, Inborn (Phase 2)

Hyperlipidemias (Phase 1)

Hyperlipoproteinemias (Phase 1)

Macular Degeneration (Phase 2)

Pain, Postoperative (Phase 3)

Prostatic Neoplasms (Phase 3)

Retinal Degeneration (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 19